Albemarle Corp. has entered into a manufacturing agreement with Anthera Pharmaceuticals in preparation for the Phase III trial of Varespladib (A-002), a potential new, oral anti-inflammatory drug for treating preconditions that can lead to heart disease. Anthera licensed the drug from Eli Lilly.     Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. The agreement also provides an option for the commercial production of Varespladib in the fut...